ClinicalTrials.gg
Active, not recruitingNCT06785506ADAPT-HFpEFUpdated Oct 7, 2026

Multiple-biomarker Approach for Individualized Treatment of Heart Failure With Preserved Ejection Fraction

An observational study in Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic and Chronic Heart Failure, sponsored by Erasmus Medical Center. Active, not recruiting at 6 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Erasmus Medical Center · Observational

How we know

Updated Oct 7, 2026Now Active, not recruitingStudy documents posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Heart Failure, Diastolic with a site in Netherlands — 3 open to participants now, 5 under way, none of them phase 3. Heart Failure, Diastolic · Netherlands.

Started
2022
with 2 others
Observational
3 of 10
2 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Erasmus Medical Center

Among the 10 studies in Heart Failure, Diastolic with a site in Netherlands, this one is one of 3 that started in 2022, is one of 3 observational ones, and was the 8th registered.

Heart Failure, Diastolic

199 studies on the registry are indexed under Heart Failure, Diastolic; 44 are open to participants now.

Browse Heart Failure, Diastolic studies →

Open to participants now

3 of the 10 studies in Heart Failure, Diastolic with a site in Netherlands are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 29 Heart Failure, Diastolic studies recruiting now, 21 (72%) set no upper age limit and 4 (14%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Heart Failure, Diastolic with a site in Netherlands, or all of them as a file.
02

Study summary

The primary objective is to investigate the association between temporal evolutions of blood biomarkers and clinical adverse events, in order to produce a dynamic, individual, and accurate prediction model for patients with HFpEF.

Moreover several secondary objectives will be investigated.

Read the detailed description

This is a prospective, observational multi-center cohort study which will be conducted at the cardiology departments of the Erasmus Medical Centre (EMC) as well as five other hospitals. A total of 200 HFpEF patients will be included in the study via the outpatient clinics. The follow-up period will constitute a minimum of 2 years and a maximum of 3.5 years. Clinical data will be collected at baseline and blood samples will be collected at baseline and subsequently every 6 months.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction
  • Heart Failure, Diastolic
  • Chronic Heart Failure

Keywords

  • HFpEF
  • Heart failure
  • preserved ejection fraction
  • biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with a (suspected) diagnosis of HFpEF will be recruited through the Cardiology outpatient clinics of the Erasmus MC and five other hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 18 years or older
  • Capable of understanding and signing
  • A diagnosis of HFpEF according to the HFA-PEFF diagnostic algorithm of the ESC or/and a high (90%) probability of HFpEF according to the H2FPEF score, i.e. a score of 6 or higher.

Exclusion criteria

Exclusion Criteria:

  • History of ≤40%
  • Scheduled for surgery or intervention for both coronary and non-coronary indication within 6 months of inclusion
  • Impaired renal function, defined as \< 20 mL/min/1.73 m2 (CKD-EPI) or requiring dialysis at the time of screening
  • Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the at screening
  • Gold stage IV
  • Congenital heart disease
  • Pregnancy
  • Coexistent condition with of \<1 year
  • Unlikely to appear at all scheduled follow-up visits
  • Linguistic barrier
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Heart failure patients visiting the outpatient clinic

    Heart failure patients visiting the outpatient clinic

06

What researchers measure

Primary outcomes

  1. The primary endpoint is the number of participants with a combined endpoint of: urgent visit resulting in intravenous therapy for HF, hospital readmission for acute or worsened HF, and cardiovascular death.

    This is a composite endpoint; therefore, the first occurrence of any of the described components will result in the endpoint being met for an individual patient.

    Time frame: Every 6 months, up to 3,5 years

Secondary outcomes

  1. Number of participants with urgent visit resulting in intravenous therapy for heart failure

    Time frame: Every 6 months, up to 3,5 years

  2. Number of patients with hospital readmission for acute or worsened HF

    Time frame: Every 6 months, up to 3.5 years

  3. Number of participants with cardiovascular death.

    Time frame: Every 6 months, up to 3.5 years

  4. Number of participants with the combined endpoint urgent visit resulting in intravenous therapy for HF, hospital readmission for acute or worsened HF, and all-cause death.

    This is a composite endpoint; therefore, the first occurrence of any of the described components will result in the endpoint being met for an individual patient.

    Time frame: Every 6 months, up to 3,5 years

  5. Number of partcipants with all-cause death

    Time frame: Every 6 months, up to 3,5 years

  6. Number of participants with the combined endpoint of myocardial infarction (fatal and non-fatal), stroke (fatal and non-fatal), percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG)

    This is a composite endpoint; therefore, the first occurrence of any of the described components will result in the endpoint being met for an individual patient.

    Time frame: Every 6 months, up to 3,5 years

  7. Number of participants with cardiovascular disease (includes all of the above-mentioned components, except all-cause death)

    This is a composite endpoint; therefore, the first occurrence of any of the described components will result in the endpoint being met for an individual patient.

    Time frame: Every 6 months, up to 3,5 years

07

Study locations

6 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Nov 2026, 47 months after the start.

Of 27 observational studies under Heart Failure, Diastolic, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 130. This study's planned 47 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Sep 2026 → Nov 2026 and completion Sep 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jan 21, 2025
StartActual
Nov 25, 2022
Primary completionEst.
Nov 1, 2026was Sep 2026
CompletionEst.
Nov 1, 2026was Sep 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 7, 2026
Sites
6 sites added, 6 sites removed
Show 6 added (6 Netherlands)
  • Noordwest Ziekenhuisgroep · Alkmaar, Netherlands
  • Amsterdam UMC · Amsterdam, Netherlands
  • OLVG Ziekenhuis · Amsterdam, Netherlands
  • Franciscus Gasthuis & Vlietland Ziekenhuis · Rotterdam, Netherlands
  • Erasmus MC · Rotterdam, Netherlands
  • Ikazia Ziekenhuis · Rotterdam, Netherlands
Show 6 removed
  • Noordwest Ziekenhuisgroep · Alkmaar, Netherlands
  • Amsterdam UMC · Amsterdam, Netherlands
  • OLVG Ziekenhuis · Amsterdam, Netherlands
  • Franciscus Gasthuis & Vlietland Ziekenhuis · Rotterdam, Netherlands
  • Erasmus MC · Rotterdam, Netherlands
  • Ikazia Ziekenhuis · Rotterdam, Netherlands
Oct 7, 2026
Primary completion
Sep 1, 2026→Nov 1, 2026
Oct 7, 2026
Study completion
Sep 1, 2026→Nov 1, 2026
Oct 7, 2026
Eligibility
Revised
Oct 7, 2026
Sponsor
Collaborators added: Universitair Ziekenhuis Brussel; collaborators removed: Free University Medical Center
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Recruiting→Active, not recruiting
    6 sites added, 6 sites removed
    Show 6 added (6 Netherlands)
    • Noordwest Ziekenhuisgroep · Alkmaar, Netherlands
    • Amsterdam UMC · Amsterdam, Netherlands
    • OLVG Ziekenhuis · Amsterdam, Netherlands
    • Franciscus Gasthuis & Vlietland Ziekenhuis · Rotterdam, Netherlands
    • Erasmus MC · Rotterdam, Netherlands
    • Ikazia Ziekenhuis · Rotterdam, Netherlands
    Show 6 removed
    • Noordwest Ziekenhuisgroep · Alkmaar, Netherlands
    • Amsterdam UMC · Amsterdam, Netherlands
    • OLVG Ziekenhuis · Amsterdam, Netherlands
    • Franciscus Gasthuis & Vlietland Ziekenhuis · Rotterdam, Netherlands
    • Erasmus MC · Rotterdam, Netherlands
    • Ikazia Ziekenhuis · Rotterdam, Netherlands
    Primary completion Sep 1, 2026→Nov 1, 2026
    Study completion Sep 1, 2026→Nov 1, 2026
    Eligibility Revised
    Sponsor Collaborators added: Universitair Ziekenhuis Brussel; collaborators removed: Free University Medical Center
    + 6 other changes: identifiers, verification date, oversight details, conditions, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06785506
Collaborators
Ikazia Hospital, Rotterdam, Franciscus Gasthuis & Vlietland (Hospital), OLVG, Universitair Ziekenhuis Brussel, Noordwest Ziekenhuisgroep
Responsible party
Isabella Kardys (Prof. dr., MD PhD, Erasmus Medical Center) — Principal investigator
First posted
Jan 21, 2025
Start date
Nov 25, 2022
Primary completion
Nov 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Oct 7, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion